Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Relating oxygen partial pressure, saturation and content: the haemoglobin-oxygen dissociation curve.

Collins JA, Rudenski A, Gibson J, Howard L, O'Driscoll R.

Breathe (Sheff). 2015 Sep;11(3):194-201. doi: 10.1183/20734735.001415. Review.

2.

An audit of hypoxaemia, hyperoxaemia, hypercapnia and acidosis in blood gas specimens.

O'Driscoll BR, Rudenski A, Turkington PM, Howard LS.

Eur Respir J. 2012 Jan;39(1):219-21. doi: 10.1183/09031936.00042711. No abstract available.

3.

The limitations of routine total digoxin immunoassay in patients with advanced chronic kidney disease.

Sharma R, Guy M, Rudenski A, Lamerton E, Kalra PA.

QJM. 2009 Oct;102(10):747-50. doi: 10.1093/qjmed/hcp088. Epub 2009 Jul 14. No abstract available.

PMID:
19602599
4.

The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study.

New JP, Aung T, Baker PG, Yongsheng G, Pylypczuk R, Houghton J, Rudenski A, New RP, Hegarty J, Gibson JM, O'Donoghue DJ, Buchan IE.

Diabet Med. 2008 May;25(5):564-9. doi: 10.1111/j.1464-5491.2008.02424.x.

PMID:
18445169
5.

Migration is associated with lower total, but not free testosterone levels in South Asian men.

Heald AH, Patel J, Anderson SG, Vyas A, Rudenski A, Hughes E, Panja NC, Ullah A, Prabhakaran D, Reddy S, Durrington P, Gibson JM, Laing I, Bhatnagar D, Cruickshank JK.

Clin Endocrinol (Oxf). 2007 Nov;67(5):651-5. Epub 2007 Sep 28.

PMID:
17900299
6.

Change in pancreatic B-cell function (HOMA-B) varies in different populations with similar genetic backgrounds but different environments.

Heald AH, Anderson SG, Patel J, Rudenski A, Vyas A, Yates A, Hughes E, Prabharakan D, Reddy S, Durrington P, Gibson JM, Bhatnagar D, Cruickshank JK, Laing I.

Diabet Med. 2007 Feb;24(2):145-53.

PMID:
17257276
7.

Time to move from serum creatinine to eGFR.

New JP, O'Donoghue DJ, Middleton RJ, Rudenski A, Dasgupta I, Bilous RW, Marshall SM.

Diabet Med. 2006 Oct;23(10):1047-9. No abstract available.

PMID:
16978366
8.

Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.

Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM.

Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):371-6.

PMID:
16915540
9.

Investigation into possible causes of interference in serum testosterone measurement in women.

Heald AH, Butterworth A, Kane JW, Borzomato J, Taylor NF, Layton T, Kilpatrick ES, Rudenski A.

Ann Clin Biochem. 2006 May;43(Pt 3):189-95.

PMID:
16704753
10.

Dietary intake and the insulin-like growth factor system: effects of migration in two related populations in India and Britain with markedly different dietary intake.

Heald AH, Sharma R, Anderson SG, Vyas A, Siddals K, Patel J, Bhatnagar D, Prabharkaran D, Rudenski A, Hughes E, Durrington P, Gibson JM, Cruickshank JK.

Public Health Nutr. 2005 Sep;8(6):620-7.

PMID:
16236191
11.

Marked differences in the IGF system that are associated with migration in comparable populations of Gujaratis living in Sandwell, UK, and Gujarat, India.

Heald AH, Anderson SG, Vyas A, Siddals K, Patel J, Yates AP, Bhatnagar D, Prabhakaran D, Hughes E, Rudenski A, Durrington P, Gibson JM, Cruickshank JK.

Diabetologia. 2005 Sep;48(9):1756-65. Epub 2005 Jul 22.

PMID:
16041536
12.

Screening for insulin resistance in women with polycystic ovarian syndrome.

Heald A, Whitehead S, Anderson S, Cruickshank K, Riste L, Laing I, Rudenski A, Buckler H.

Gynecol Endocrinol. 2005 Feb;20(2):84-91.

PMID:
15823827
13.

Endogenous growth theory for natural scientists.

Kealey T, Rudenski A.

Nat Med. 1998 Sep;4(9):995-9. No abstract available.

PMID:
9734383
14.
15.

Infant emmetropization: longitudinal changes in refraction components from nine to twenty months of age.

Ehrlich DL, Braddick OJ, Atkinson J, Anker S, Weeks F, Hartley T, Wade J, Rudenski A.

Optom Vis Sci. 1997 Oct;74(10):822-43.

PMID:
9383797
16.

The use of a microcomputer to automate measurement of action potential duration for both transmembrane and monophasic action potentials.

Coulshed DS, Rudenski A, Cowan JC, Coulshed SJ, Hainsworth R.

Physiol Meas. 1993 Aug;14(3):347-58.

PMID:
8401274
17.

Understanding "insulin resistance": both glucose resistance and insulin resistance are required to model human diabetes.

Rudenski AS, Matthews DR, Levy JC, Turner RC.

Metabolism. 1991 Sep;40(9):908-17.

PMID:
1895955
18.

Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.

Levy JC, Rudenski A, Burnett M, Knight R, Matthews DR, Turner RC.

Diabetologia. 1991 Jul;34(7):488-99.

PMID:
1916054
19.

Cushing's syndrome and medroxyprogesterone acetate.

Grenfell A, Rudenski A, Watts M, Wiltshire C, Day JL, Gray IP.

Lancet. 1990 Jul 28;336(8709):256. No abstract available.

PMID:
1973810
20.

Application of structural model of glucose-insulin relations to assess beta-cell function and insulin sensitivity.

Turner RC, Rudenski AS, Matthews DR, Levy JC, O'Rahilly SP, Hosker JP.

Horm Metab Res Suppl. 1990;24:66-71. Review.

PMID:
2272629
21.
22.

The glucose stimulus-response curve of the beta-cell in physically trained humans, assessed by hyperglycemic clamps.

O'Rahilly SO, Hosker JP, Rudenski AS, Matthews DR, Burnett MA, Turner RC.

Metabolism. 1988 Oct;37(10):919-23.

PMID:
3050363
23.

The beta cell glucose stimulus-response curve in normal humans assessed by insulin and C-peptide secretion rates.

Rudenski AS, Hosker JP, Burnett MA, Matthews DR, Turner RC.

Metabolism. 1988 Jun;37(6):526-34.

PMID:
3287091
24.

Pathogenesis of NIDDM--a disease of deficient insulin secretion.

Turner RC, Matthews DR, Clark A, O'Rahilly S, Rudenski AS, Levy J.

Baillieres Clin Endocrinol Metab. 1988 May;2(2):327-42. Review.

PMID:
3075895
25.

CIGMA as a tool in the study of NIDDM.

Turner RC, Rudenski AS, Hosker JP, Matthews DR, Levy JC, O'Rahilly SP.

Prog Clin Biol Res. 1988;265:13-26. No abstract available.

PMID:
3405996
26.

Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment.

Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, Pockaj B, Turner RC.

Diabet Med. 1988 Jan;5(1):36-41.

PMID:
2964326
27.

Insulin sensitivity and beta-cell function assessed by C-peptide in young adults with cystic fibrosis.

Davis TM, Batten JC, Rudenski AS, Turner RC.

Eur J Clin Invest. 1987 Feb;17(1):12-5.

PMID:
3106046
28.

Quantitative modelling of endocrine diseases as exemplified by diabetes.

Turner RC, Rudenski AS, Holman RR, Matthews DR, O'Rahilly SP.

Clin Endocrinol (Oxf). 1987 Jan;26(1):107-16. Review. No abstract available.

PMID:
3542309
29.

Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes.

O'Rahilly SP, Nugent Z, Rudenski AS, Hosker JP, Burnett MA, Darling P, Turner RC.

Lancet. 1986 Aug 16;2(8503):360-4.

PMID:
2874367
30.

Diabetes nomenclature: classification or grading of severity?

Turner RC, Holman RR, Matthews DR, O'Rahilly SP, Rudenski AS, Braund WJ.

Diabet Med. 1986 May;3(3):216-20. No abstract available.

PMID:
2951172
31.

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.

Diabetologia. 1985 Jul;28(7):412-9.

PMID:
3899825
32.

Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man.

Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, Bown EG, Turner RC.

Diabetologia. 1985 Jul;28(7):401-11.

PMID:
3899824
33.

The half-life of endogenous insulin and C-peptide in man assessed by somatostatin suppression.

Matthews DR, Rudenski AS, Burnett MA, Darling P, Turner RC.

Clin Endocrinol (Oxf). 1985 Jul;23(1):71-9.

PMID:
2863015

Supplemental Content

Loading ...
Support Center